Triple negative breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Triple negative breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk https://clinicaltrials.eu/trial/study-on-early-detection-of-triple-negative-breast-cancer-relapse-using-68ga-fapi-46-for-patients-at-high-risk/ Fri, 05 Jun 2026 10:50:43 +0000 https://clinicaltrials.eu/trial/study-on-early-detection-of-triple-negative-breast-cancer-relapse-using-68ga-fapi-46-for-patients-at-high-risk/ This clinical trial is focused on patients with triple-negative breast cancer (TNBC), a type of breast cancer that lacks three common receptors known to fuel most breast cancer growths. The study aims to detect early signs of cancer returning, known as a relapse, in patients who are at high risk. The treatment being studied involves a special imaging technique using a substance called 68Ga-FAPI-46, which is given through an intravenous infusion. This substance helps to highlight cancer cells during a scan, making it easier to see if the cancer has returned.

The purpose of the study is to evaluate a new way of monitoring patients using a method called ctDNA-based surveillance. This involves checking for tiny pieces of cancer DNA in the blood, which can indicate if the cancer is coming back. The study will compare this new method with standard monitoring techniques to see if it can help detect relapses earlier and improve survival rates. Participants will undergo regular scans and blood tests over a period of time to monitor their condition.

Throughout the study, researchers will collect information on how well the new monitoring method works, including any side effects from the 68Ga-FAPI-46 PET-CT scans. The study will also look at how the new method compares to existing imaging procedures, such as 18F-FDG PET-CT, in terms of detecting cancer spread. The trial is expected to run until 2028, with the goal of improving early detection and treatment strategies for patients with high-risk triple-negative breast cancer.

]]> Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-and-pembrolizumab-in-patients-with-stage-ii-iii-triple-negative-early-breast-cancer/ Tue, 02 Jun 2026 04:17:42 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-and-pembrolizumab-in-patients-with-stage-ii-iii-triple-negative-early-breast-cancer/ This clinical trial is studying triple-negative early breast cancer, a type of breast cancer that does not have the three common markers used to guide treatment. The purpose of the study is to compare two treatment approaches given before surgery: sacituzumab govitecan together with pembrolizumab, and standard chemotherapy.

The treatment is given as an intravenous infusion, which means it is delivered through a vein. The study looks at whether the new drug combination can help keep the cancer from coming back and whether it can remove all signs of invasive cancer in the breast and nearby lymph nodes before surgery. The course of the study includes treatment over a planned period, followed by surgery and later follow-up visits to monitor health over time.

Some medical terms used in the study include neoadjuvant, which means treatment given before surgery, and EFS, which means the length of time without a cancer-related event such as the cancer returning or worsening. The study also records side effects and overall health changes during follow-up.

]]> Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer https://clinicaltrials.eu/trial/testing-sacituzumab-govitecan-and-trastuzumab-deruxtecan-in-alternating-pattern-for-patients-with-her2-low-triple-negative-breast-cancer/ Thu, 30 Apr 2026 13:08:17 +0000 https://clinicaltrials.eu/trial/testing-sacituzumab-govitecan-and-trastuzumab-deruxtecan-in-alternating-pattern-for-patients-with-her2-low-triple-negative-breast-cancer/ This study is looking at patients with triple-negative breast cancer that is HER2-low and has spread to other parts of the body or has grown locally in a way that cannot be removed by surgery. Triple-negative breast cancer is a type of breast cancer where the cancer cells do not have certain receptors that are commonly found in other breast cancers, specifically having very low levels of estrogen and progesterone receptors. HER2-low means that the cancer cells have a small amount of a protein called HER2 on their surface. The study will test two medications called sacituzumab govitecan and trastuzumab deruxtecan, which are given through a vein. These medications will be given in an alternating pattern, meaning patients will switch between the two treatments rather than receiving just one continuously.

The purpose of the study is to see if using both medications in this alternating way helps patients live longer compared to using sacituzumab govitecan alone. The study will also look at how well the treatment works by measuring whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how the treatment affects their quality of life. Researchers will also carefully track any side effects or unwanted reactions that patients experience during the treatment to understand how safe and tolerable this approach is.

During the study, patients will be randomly assigned to receive either the alternating combination of both medications or sacituzumab govitecan alone. Both medications are given through an infusion into a vein, and the treatment continues for a period of weeks with regular monitoring visits. Throughout the study, doctors will perform regular check-ups, blood tests, and scans to see how the cancer is responding to treatment and to monitor the patient’s overall health and heart function. Patients will also be asked to complete questionnaires about their quality of life and how they are feeling during treatment.

]]> A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer https://clinicaltrials.eu/trial/a-study-comparing-datopotamab-deruxtecan-with-durvalumab-versus-datopotamab-deruxtecan-alone-for-patients-with-pdl1-negative-metastatic-triple-negative-breast-cancer/ Thu, 30 Apr 2026 13:08:15 +0000 https://clinicaltrials.eu/trial/a-study-comparing-datopotamab-deruxtecan-with-durvalumab-versus-datopotamab-deruxtecan-alone-for-patients-with-pdl1-negative-metastatic-triple-negative-breast-cancer/ This study is looking at metastatic triple-negative breast cancer that is PDL1-negative. Triple-negative breast cancer is a type of breast cancer where the cancer cells do not have receptors for estrogen, progesterone, or a protein called HER2. Metastatic means the cancer has spread to other parts of the body beyond the breast. PDL1-negative refers to cancer cells that do not have a specific protein on their surface. The study will test two different treatment approaches. One group of patients will receive a combination of two medications called Datopotamab deruxtecan and Durvalumab, while another group will receive only Datopotamab deruxtecan. Both medications are given through a vein as an infusion. The purpose of the study is to see if the combination of the two medications works better than using just one medication alone in stopping the cancer from getting worse.

The study will compare how long patients go without their cancer getting worse when they receive the combination treatment versus the single medication. Patients will be randomly assigned to one of the two treatment groups, meaning they will not be able to choose which treatment they receive. During the study, patients will have regular check-ups and scans to see how well the treatment is working. The scans will be done using either computed tomography or magnetic resonance imaging, which are imaging techniques that create detailed pictures of the inside of the body. The study will also look at how long patients live overall, how many patients respond to the treatment, and how long any response to treatment lasts.

Additionally, the study will measure the overall benefit patients receive from the treatment and will track any side effects that occur. Quality of life will also be assessed using questionnaires to understand how the treatment affects patients’ daily lives and overall well-being. Patients will need to provide tissue samples from their cancer so that tests can be done to confirm they are eligible for the study. Treatment can continue for up to 39 months depending on how well it works and how well it is tolerated.

]]> Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment https://clinicaltrials.eu/trial/study-of-pembrolizumab-capecitabine-or-olaparib-in-patients-with-early-stage-triple-negative-breast-cancer-and-remaining-disease-after-initial-treatment/ Wed, 29 Apr 2026 15:09:47 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-capecitabine-or-olaparib-in-patients-with-early-stage-triple-negative-breast-cancer-and-remaining-disease-after-initial-treatment/ This study focuses on individuals with early-stage Triple Negative Breast Cancer who still have residual disease, which means some cancer cells remain in the body, after receiving initial treatment. The initial treatment involves neoadjuvant therapy, which is medicine given before surgery to shrink a tumor. The purpose of this study is to evaluate the benefit of adding pembrolizumab to standard follow-up treatments.

Participants in this study will receive different combinations of medications as part of their adjuvant therapy, which is treatment given after the main treatment to lower the risk of the cancer returning. Some individuals will receive pembrolizumab along with capecitabine or olaparib. Other participants may receive tegafur, gimeracil, and oteracil. These medications are administered either through an intravenous infusion, which is medicine delivered directly into a vein, or by taking pills at home.

]]> Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer https://clinicaltrials.eu/trial/study-comparing-datopotamab-deruxtecan-with-or-without-durvalumab-to-chemotherapy-with-pembrolizumab-for-patients-with-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:08:28 +0000 https://clinicaltrials.eu/trial/study-comparing-datopotamab-deruxtecan-with-or-without-durvalumab-to-chemotherapy-with-pembrolizumab-for-patients-with-triple-negative-breast-cancer/ This study involves patients with triple-negative breast cancer that has spread to other parts of the body or has come back in a way that cannot be removed by surgery. Triple-negative breast cancer is a type of breast cancer that does not have certain receptors on the cancer cells, which makes it different from other breast cancer types. The study will use several different medications. The main medication being tested is datopotamab deruxtecan, which has the code name DS-1062a. This medication may be given alone or together with another medication called durvalumab, which is also known as IMFINZI. These treatments will be compared to a combination of pembrolizumab plus one of the following chemotherapy medications chosen by the doctor: paclitaxel, nab-paclitaxel, or a combination of gemcitabine and carboplatin. All participants in the study must have cancer that tests positive for a marker called PD-L1, which is a protein found on some cancer cells. Some participants may also receive other medications such as infliximab or mycophenolate mofetil as supportive treatments.

The purpose of this study is to find out if treatment with datopotamab deruxtecan combined with durvalumab works better than the standard chemotherapy combinations with pembrolizumab in stopping the cancer from getting worse or spreading further. The study will measure how long patients live without their cancer getting worse, and will also look at how long patients live overall, how many patients respond to treatment, and how long those responses last. The study will also examine the safety of these treatments and how they affect quality of life and symptoms.

Participants will be randomly assigned to receive either datopotamab deruxtecan with or without durvalumab, or one of the chemotherapy options combined with pembrolizumab. All medications in this study are given through a vein as an infusion. During the study, participants will have regular check-ups that include scans to see how the cancer is responding to treatment. The doctors will also monitor for any side effects and collect information about how participants are feeling. Blood samples will be taken to measure the levels of medication in the body and to check how the immune system responds to the treatment. The study will continue until 2029, and participants will be followed even after they stop taking the study medication to see how they are doing.

]]> A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer https://clinicaltrials.eu/trial/a-study-testing-zimberelimab-domvanalimab-and-sacituzumab-govitecan-for-patients-with-pd-l1-positive-advanced-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:08:04 +0000 https://clinicaltrials.eu/trial/a-study-testing-zimberelimab-domvanalimab-and-sacituzumab-govitecan-for-patients-with-pd-l1-positive-advanced-triple-negative-breast-cancer/ This study is looking at a specific type of breast cancer called triple-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery. Triple-negative breast cancer is a form of breast cancer where the cancer cells do not have certain proteins on their surface, which makes it different from other types of breast cancer. The study focuses on patients whose cancer tests positive for a marker called PD-L1, which is a protein found on some cancer cells. The treatment being studied involves a combination of three medications given through a vein: zimberelimab (also known by the code name AB122), domvanalimab (also known by the code name AB154), and sacituzumab govitecan (marketed as Trodelvy). These medications work in different ways to help the body fight cancer cells. This combination is being tested as the first treatment for patients who have not yet received any therapy for their advanced disease.

The main goal of this study is to find out how well this three-drug combination works in shrinking or stopping the growth of tumors in patients with this specific type of breast cancer. The study will measure how many patients experience a reduction in the size of their tumors or have their tumors disappear completely. The researchers will also look at how long patients live without their disease getting worse, how long patients survive overall, and how long any positive response to treatment lasts. Additionally, the study will examine the safety of this treatment combination and any side effects that may occur.

Patients in this study will receive the three medications through infusions into a vein at specific time intervals over a treatment period that can last up to twelve months. Throughout the study, patients will have regular check-ups that include imaging scans such as CT scans or MRI scans to see how the tumors are responding to treatment. Blood and stool samples will be collected at various points during the study. Patients will also need to provide a tissue sample from their tumor, either from a previous biopsy or from a new biopsy taken before treatment starts. The study requires that patients have measurable disease that can be tracked using imaging tests, and they must not have received any previous treatment for their advanced cancer, although some prior treatment in earlier stages of the disease is allowed if enough time has passed.

]]> Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment https://clinicaltrials.eu/trial/study-of-izalontamab-brengitecan-compared-to-standard-chemotherapy-in-untreated-triple-negative-or-er-low-her2-negative-breast-cancer-patients-not-eligible-for-anti-pd1-pd-l1-treatment/ Wed, 29 Apr 2026 15:07:35 +0000 https://clinicaltrials.eu/trial/study-of-izalontamab-brengitecan-compared-to-standard-chemotherapy-in-untreated-triple-negative-or-er-low-her2-negative-breast-cancer-patients-not-eligible-for-anti-pd1-pd-l1-treatment/ This study focuses on Triple-negative Breast Cancer and ER-low, HER2-negative Breast Cancer that cannot be removed by surgery or has spread to other parts of the body. The study compares a new medicine called izalontamab brengitecan (also known as BL-B01D1) with standard chemotherapy treatments including paclitaxel, paclitaxel albumin-bound, capecitabine, or a combination of carboplatin and gemcitabine.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

]]> Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-with-or-without-durvalumab-compared-to-standard-treatment-for-patients-with-stage-i-iii-triple-negative-breast-cancer-who-have-remaining-cancer-after-initial-therapy/ Wed, 29 Apr 2026 15:07:16 +0000 https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-with-or-without-durvalumab-compared-to-standard-treatment-for-patients-with-stage-i-iii-triple-negative-breast-cancer-who-have-remaining-cancer-after-initial-therapy/ This study focuses on patients with Triple-negative Breast Cancer in stages I-III who have remaining disease after initial treatment before surgery. The main treatment being tested is Datopotamab deruxtecan (also known as Dato-DXd), which may be given alone or combined with another medication called Durvalumab. These will be compared to other standard treatment options that may include Capecitabine, Pembrolizumab, Infliximab, or Mycophenolate mofetil.

The purpose of this research is to determine if Datopotamab deruxtecan combined with Durvalumab works better than currently available treatments in preventing the cancer from returning after surgery. The medications being studied are given through an intravenous line directly into the bloodstream, except for Capecitabine and Mycophenolate mofetil which are taken as tablets by mouth.

During the study, participants will be randomly assigned to receive either Datopotamab deruxtecan alone, Datopotamab deruxtecan with Durvalumab, or one of the standard treatment options. The study will monitor how long patients remain free of cancer after starting treatment and track their overall health and well-being throughout the study period.

]]> Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer https://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-pembrolizumab-and-chemotherapy-combination-for-early-stage-triple-negative-breast-cancer-or-hormone-receptor-low-positive-her2-negative-breast-cancer/ Wed, 29 Apr 2026 15:07:08 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-pembrolizumab-and-chemotherapy-combination-for-early-stage-triple-negative-breast-cancer-or-hormone-receptor-low-positive-her2-negative-breast-cancer/ This clinical trial studies the treatment of triple-negative breast cancer and hormone receptor-low positive/HER2-negative breast cancer in its early stages. The study evaluates a new treatment approach using sacituzumab tirumotecan (also known as MK-2870) followed by carboplatin and paclitaxel, compared to standard chemotherapy. Both treatment options will be combined with pembrolizumab (Keytruda), a medication that helps the immune system fight cancer cells.

The treatment plan involves giving medications before surgery (neoadjuvant therapy) to shrink the tumor. The study medications are given through an intravenous infusion directly into the bloodstream. Some participants will receive the new combination with sacituzumab tirumotecan, while others will receive standard chemotherapy which may include doxorubicin, epirubicin, or cyclophosphamide. All participants will also receive dexamethasone to help manage side effects, and some may receive capecitabine as part of their treatment.

The main purpose of this research is to determine whether the new treatment combination is more effective at eliminating cancer cells before surgery compared to standard chemotherapy. The study will also track how long participants remain free of cancer after treatment and monitor their overall survival. Researchers will carefully watch for any side effects and evaluate how the treatments affect participants’ quality of life.

]]> Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression https://clinicaltrials.eu/trial/evaluating-sacituzumab-tirumotecan-alone-or-with-pembrolizumab-compared-to-standard-treatment-in-untreated-patients-with-metastatic-triple-negative-breast-cancer-with-low-pd-l1-expression/ Wed, 29 Apr 2026 15:06:25 +0000 https://clinicaltrials.eu/trial/evaluating-sacituzumab-tirumotecan-alone-or-with-pembrolizumab-compared-to-standard-treatment-in-untreated-patients-with-metastatic-triple-negative-breast-cancer-with-low-pd-l1-expression/ This study focuses on triple-negative breast cancer that has spread to other parts of the body or cannot be surgically removed. The study tests a new drug called sacituzumab tirumotecan (also known as MK-2870), both alone and in combination with another drug called pembrolizumab (KEYTRUDA). These treatments will be compared to standard treatment options which include paclitaxel, albumin-bound paclitaxel, or a combination of gemcitabine and carboplatin.

The purpose of this research is to determine how well sacituzumab tirumotecan works, both by itself and when combined with pembrolizumab, compared to standard treatments. The study will look at how these treatments affect cancer growth and patient survival. All medications will be given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either sacituzumab tirumotecan alone, sacituzumab tirumotecan with pembrolizumab, or one of the standard treatment options. The study will monitor how the cancer responds to treatment and track any side effects that may occur. Patients will also complete questionnaires about their quality of life during treatment.

]]> Study on Atorvastatin’s Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-atorvastatins-role-in-enhancing-immunotherapy-for-patients-with-triple-negative-breast-cancer-and-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:06:11 +0000 https://clinicaltrials.eu/trial/study-on-atorvastatins-role-in-enhancing-immunotherapy-for-patients-with-triple-negative-breast-cancer-and-non-small-cell-lung-cancer/ This clinical trial, known as the STARK trial, is investigating the use of Atorvastatin (a type of statin medication commonly used to lower cholesterol) in combination with immunotherapy (treatments that help the immune system fight cancer) for patients with Triple Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC). The purpose of the study is to determine if adding Atorvastatin can improve the effectiveness of immunotherapy treatments like pembrolizumab in these cancer types.

For breast cancer patients, the study involves receiving Atorvastatin alongside standard immunotherapy and chemotherapy before surgery. For lung cancer patients, Atorvastatin will be given with first-line immunotherapy. The researchers will collect tumor samples and blood samples at different timepoints to analyze how the combination treatment affects the immune response in the tumor and the presence of cancer DNA in the blood.

The trial will monitor both how well the treatment works against the cancer and any side effects that may occur. Various advanced laboratory techniques will be used to understand how Atorvastatin affects the immune system’s response to cancer and to identify markers that might predict which patients will benefit most from this combination approach.

]]> Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification https://clinicaltrials.eu/trial/study-of-bt8009-for-patients-with-advanced-breast-cancer-with-nectin4-amplification/ Wed, 29 Apr 2026 15:05:07 +0000 https://clinicaltrials.eu/trial/study-of-bt8009-for-patients-with-advanced-breast-cancer-with-nectin4-amplification/ This clinical trial is focused on studying a type of breast cancer known as NECTIN4 Amplified Advanced Breast Cancer. The treatment being tested in this study is called zelenectide pevedotin, which is administered as a solution through an intravenous infusion. The purpose of the study is to evaluate how effective this treatment is in patients with this specific type of breast cancer.

Participants in the study will receive the treatment and be monitored over a period of time to observe any changes in their condition. The study aims to measure the response of the cancer to the treatment, looking for signs of improvement or stability. The treatment will be given in cycles, and the health of the participants will be closely watched by the study team to ensure safety and to gather information on how the treatment affects the cancer.

The study will also collect data on any side effects experienced by participants, as well as other health indicators such as laboratory test results and vital signs. This information will help researchers understand the overall impact of zelenectide pevedotin on patients with NECTIN4 Amplified Advanced Breast Cancer and contribute to the development of new treatment options for this disease.

]]> Study on the Effects of INT230-6, Vinblastine Sulfate, and Cisplatin in Patients with Early Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-int230-6-vinblastine-sulfate-and-cisplatin-in-patients-with-early-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:04:31 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-int230-6-vinblastine-sulfate-and-cisplatin-in-patients-with-early-triple-negative-breast-cancer/ This clinical trial is focused on studying the effects of a treatment for early triple-negative breast cancer (TNBC). The treatment being tested is called INT230-6, which is a solution for injection containing two active substances: vinblastine sulfate and cisplatin. These substances are known to be used in cancer treatment. The study aims to understand how well this treatment works when injected directly into the tumor.

The purpose of the study is to determine the clinical activity of intratumoral INT230-6 in patients with early TNBC. Participants in the study will receive the treatment by direct injection into their tumor, followed by additional treatment with a combination of chemotherapy and immunotherapy. The study is designed to observe the effects of this treatment approach over a period of time, with the goal of understanding its impact on the cancer.

Throughout the study, researchers will monitor the response of the cancer to the treatment, including any changes in the size of the tumor and the overall health of the participants. The study will also look at the rate of successful breast-conserving surgeries and any side effects experienced by participants. This information will help determine the effectiveness and safety of the treatment for patients with early-stage triple-negative breast cancer.

]]> Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer https://clinicaltrials.eu/trial/study-of-patritumab-deruxtecan-and-pembrolizumab-for-patients-with-high-risk-early-stage-triple-negative-or-hormone-receptor-low-positive-breast-cancer/ Wed, 29 Apr 2026 15:04:28 +0000 https://clinicaltrials.eu/trial/study-of-patritumab-deruxtecan-and-pembrolizumab-for-patients-with-high-risk-early-stage-triple-negative-or-hormone-receptor-low-positive-breast-cancer/ This clinical trial is focused on studying treatments for a type of breast cancer known as high-risk early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer. The study involves several medications, including patritumab deruxtecan (also known as MK-1022), pembrolizumab (also known as Keytruda), carboplatin, paclitaxel, epirubicin hydrochloride, doxorubicin hydrochloride, cyclophosphamide, capecitabine, and olaparib. These medications are used in different combinations to explore their safety and effectiveness in treating the specified types of breast cancer.

The purpose of the study is to evaluate the safety and effectiveness of these treatments when given in different sequences. Participants will receive these medications through intravenous infusion, which means the medicine is given directly into a vein, or orally, which means the medicine is taken by mouth. The study will compare the effects of these treatments when given before or after surgery, as well as their impact on the cancer’s response to treatment.

Throughout the study, participants will be monitored for any side effects and the overall response of their cancer to the treatment. The study aims to determine the best treatment sequence to improve outcomes for patients with these specific types of breast cancer. The trial will continue for several years to gather comprehensive data on the effectiveness and safety of the treatments being tested.

]]> Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-carboplatin-and-paclitaxel-for-patients-with-stage-i-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:04:23 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-carboplatin-and-paclitaxel-for-patients-with-stage-i-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple-negative breast cancer (TNBC), specifically in its early stage, referred to as stage I. The study aims to evaluate the effectiveness of a treatment combination that includes three medications: pembrolizumab, carboplatin, and paclitaxel. Pembrolizumab, also known by its code name MK-3475, is a medication that helps the immune system fight cancer cells. Carboplatin and paclitaxel are chemotherapy drugs that work by stopping the growth of cancer cells.

The purpose of this study is to assess how well this combination of medications can eliminate cancer cells before surgery. Participants will receive these medications over a period of time, and their response to the treatment will be closely monitored. The study will involve regular check-ups and assessments to see how the cancer responds to the treatment. The ultimate goal is to see if the cancer can be completely removed by the time of surgery.

Throughout the study, participants will undergo various tests and provide samples to help researchers understand the treatment’s effects. The study will also monitor any side effects that may occur during the treatment. This research is important for finding more effective ways to treat early-stage triple-negative breast cancer and improve outcomes for patients with this type of cancer.

]]> Study of [68Ga]Ga-PentixaFor PET-CT Imaging in Patients with Metastatic Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-the-use-of-68gaga-pentixafor-for-detecting-tumors-in-patients-with-metastatic-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:04:08 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-68gaga-pentixafor-for-detecting-tumors-in-patients-with-metastatic-triple-negative-breast-cancer/ This study focuses on patients with triple-negative breast cancer that has spread to other parts of the body (metastatic). The study will use a new imaging substance called [68Ga]Ga-PentixaFor, which is given as an injection into a vein. This substance is used with special imaging tests called PET-CT scans to detect cancer cells in the body.

The purpose of this study is to compare how well this new imaging method can detect cancer spots compared to a standard imaging test that uses a different substance called [18F]FDG. The study will look at whether both types of scans find the same cancer spots and how they match up with each other. Patients will receive the new imaging substance as a single injection, and pictures of their body will be taken using special cameras.

During the study, doctors will monitor patients for 60 minutes after receiving the injection to check for any side effects. The total amount of the imaging substance used will not exceed 200 megabecquerels (a measure of radioactivity). The imaging will be done twice during the study: once at the beginning and again if the cancer shows signs of getting worse.

]]> Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment https://clinicaltrials.eu/trial/study-on-pembrolizumab-for-patients-with-early-triple-negative-breast-cancer-responding-well-to-initial-treatment/ Wed, 29 Apr 2026 15:03:53 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-for-patients-with-early-triple-negative-breast-cancer-responding-well-to-initial-treatment/ This clinical trial is focused on patients with early-stage triple-negative breast cancer who have shown a strong response to initial treatments. The study is examining the use of a medication called pembrolizumab, which is given as a solution through an intravenous infusion. Pembrolizumab is a type of treatment that helps the immune system fight cancer cells. The trial aims to determine if simply observing patients after surgery is as effective as continuing treatment with pembrolizumab for six months in preventing the cancer from coming back.

Participants in the study will have already received standard chemotherapy and pembrolizumab before surgery and achieved a complete response, meaning no signs of cancer were found in the breast or lymph nodes. The study will compare two groups: one group will continue to receive pembrolizumab after surgery, while the other group will be closely monitored without further treatment. The goal is to see if both approaches offer similar protection against the cancer returning.

The trial will also look at the safety and side effects of pembrolizumab, as well as the overall quality of life of the participants. This includes monitoring for any new symptoms or health issues that may arise during the study. The study is expected to continue for several years to gather enough information to make a clear comparison between the two approaches. Participants will be regularly checked to ensure their health and well-being throughout the study period.

]]> Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-datopotamab-deruxtecan-compared-to-chemotherapy-in-adults-with-advanced-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:03:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-datopotamab-deruxtecan-compared-to-chemotherapy-in-adults-with-advanced-triple-negative-breast-cancer/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called Datopotamab deruxtecan (also known as Dato-DXd) for patients with a specific type of breast cancer known as triple-negative breast cancer (TNBC). This type of breast cancer is characterized by the absence of three common receptors known to fuel most breast cancer growths. The study is designed for patients whose cancer has either returned and cannot be surgically removed or has spread to other parts of the body, and who are not suitable for a type of treatment called PD-1/PD-L1 inhibitor therapy.

The trial will compare the new treatment, Datopotamab deruxtecan, with standard chemotherapy options, which include medications such as carboplatin, paclitaxel, capecitabine, and eribulin mesylate. These medications are commonly used in chemotherapy to treat various types of cancer by stopping the growth of cancer cells. The purpose of the study is to determine if the new treatment is more effective in prolonging the time patients live without their disease getting worse and in improving overall survival compared to the standard chemotherapy options.

Participants in the study will be randomly assigned to receive either the new treatment or one of the standard chemotherapy options. The treatment will be administered through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the participants’ health and response to the treatment over time to gather information on the effectiveness and safety of Datopotamab deruxtecan compared to the standard treatments. The trial aims to provide valuable insights into better treatment options for patients with triple-negative breast cancer.

]]> Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel for Patients with Metastatic Triple-Negative PD-L1 Positive Breast Cancer https://clinicaltrials.eu/trial/study-of-atezolizumab-carboplatin-and-nab-paclitaxel-for-patients-with-metastatic-triple-negative-pd-l1-positive-breast-cancer/ Wed, 29 Apr 2026 15:02:55 +0000 https://clinicaltrials.eu/trial/study-of-atezolizumab-carboplatin-and-nab-paclitaxel-for-patients-with-metastatic-triple-negative-pd-l1-positive-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as metastatic triple-negative PD-L1 positive breast cancer. This is a form of breast cancer that has spread to other parts of the body and does not have certain receptors that are commonly found in other breast cancers. The study is testing a combination of three treatments: atezolizumab, carboplatin, and paclitaxel albumin-bound. Atezolizumab is a type of medicine called a monoclonal antibody, which helps the immune system fight cancer. Carboplatin and paclitaxel albumin-bound are chemotherapy drugs that help stop the growth of cancer cells.

The purpose of this study is to gather preliminary evidence on how effective this combination of treatments is as a first-line therapy, meaning it is the first treatment given for this type of cancer. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for up to 12 months, during which time the effects of the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study aims to understand how well patients respond to this treatment combination and how it affects their overall survival over a period of two years. The trial will also look at other factors, such as the time it takes for the disease to progress and any side effects experienced by participants. This information will help determine if this combination of treatments can be an effective option for patients with this specific type of breast cancer.

]]> Study of Datopotamab Deruxtecan for Patients with Triple-Negative Breast Cancer and New or Worsening Brain Metastases https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-for-patients-with-triple-negative-breast-cancer-and-new-or-worsening-brain-metastases/ Wed, 29 Apr 2026 15:02:31 +0000 https://clinicaltrials.eu/trial/study-of-datopotamab-deruxtecan-for-patients-with-triple-negative-breast-cancer-and-new-or-worsening-brain-metastases/ This clinical trial is focused on studying triple-negative breast cancer, a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth. The study is specifically looking at patients who have newly diagnosed or progressing brain metastases, which means the cancer has spread to the brain. The treatment being tested is called Datopotamab deruxtecan, also known by its code name Dato-DXd or DS-1026a. This medication is given as a solution through an infusion into the veins.

The purpose of the study is to evaluate how well Dato-DXd can induce responses in the central nervous system (CNS) of patients with this type of breast cancer and brain metastases. During the study, participants will receive the medication and be monitored for their response to the treatment. Some participants may receive a placebo, which is a substance with no active medication. The study will observe how the cancer responds in the brain and other parts of the body, as well as track the overall survival and progression-free survival of the participants.

The study will take place over a period of time, with regular assessments to check the effectiveness of the treatment. The goal is to gather information on how well Dato-DXd works in treating brain metastases in patients with triple-negative breast cancer, providing valuable insights into potential new treatment options for this challenging condition.

]]> Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer https://clinicaltrials.eu/trial/study-of-bt-001-and-pembrolizumab-for-patients-with-advanced-solid-tumors-including-sarcoma-merkel-cell-carcinoma-melanoma-breast-and-lung-cancer/ Wed, 29 Apr 2026 15:02:29 +0000 https://clinicaltrials.eu/trial/study-of-bt-001-and-pembrolizumab-for-patients-with-advanced-solid-tumors-including-sarcoma-merkel-cell-carcinoma-melanoma-breast-and-lung-cancer/ This clinical trial is focused on studying several types of advanced cancers, including metastatic or advanced soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple-negative breast cancer, and non-small cell lung cancer. The study is testing a new treatment approach using a medication called BT-001, which is administered directly into the tumor. This treatment is being tested alone and in combination with another medication called pembrolizumab, which is given through an intravenous infusion. The purpose of the study is to evaluate the safety and effectiveness of these treatments in patients with these types of cancers.

Participants in the study will receive the treatment over a period of time, with regular monitoring to assess how their body responds to the medication. The study will look at both the local effects at the site of the tumor and the overall effects on the body. The goal is to determine the best dose of BT-001 and to see how well it works when used with pembrolizumab. Some participants may receive a placebo as part of the study to help compare the effects of the actual treatment.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. This includes regular check-ups and tests to ensure the treatment is safe and to measure its impact on the cancer. The study aims to provide valuable information on the potential benefits of combining BT-001 with pembrolizumab for treating these challenging types of cancer.

]]> Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-avelumab-for-patients-with-high-risk-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:01:58 +0000 https://clinicaltrials.eu/trial/study-on-avelumab-for-patients-with-high-risk-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple negative breast cancer. This form of cancer is called “triple negative” because the cancer cells do not have three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and HER2/neu. The treatment being tested in this study is a medication called Avelumab, which is an anti-PD-L1 antibody. This medication is given as a solution through an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to find out if taking Avelumab for one year can help improve the time patients remain free from cancer after they have already received surgery and chemotherapy aimed at curing the cancer. The study will compare patients who receive Avelumab with those who are just observed without additional treatment. Patients participating in the study will have completed their initial treatment, which includes surgery to remove the tumor and chemotherapy to kill any remaining cancer cells.

Participants in the study will be randomly assigned to either receive the Avelumab treatment or be part of the observation group. The study will last for about a year, during which time the health of the participants will be closely monitored. The main goal is to see if Avelumab can help prevent the cancer from coming back. The study will also look at overall survival, which means how long patients live after starting the study, whether or not the cancer returns. This research aims to provide more information on whether Avelumab can be an effective additional treatment for patients with high-risk triple negative breast cancer.

]]> Study on Nivolumab with Paclitaxel and Carboplatin for Early Stage Triple Negative Breast Cancer Patients https://clinicaltrials.eu/trial/study-on-nivolumab-with-paclitaxel-and-carboplatin-for-early-stage-triple-negative-breast-cancer-patients/ Wed, 29 Apr 2026 15:01:38 +0000 https://clinicaltrials.eu/trial/study-on-nivolumab-with-paclitaxel-and-carboplatin-for-early-stage-triple-negative-breast-cancer-patients/ This clinical trial is focused on studying early stage triple negative breast cancer, a type of breast cancer that does not have three common receptors known to fuel most breast cancer growths. The study is testing a treatment that combines a medication called nivolumab with chemotherapy drugs paclitaxel and carboplatin. Nivolumab, also known by its code name BMS936558, is a type of drug that helps the immune system fight cancer cells. The chemotherapy drugs, paclitaxel and carboplatin, are used to kill cancer cells directly.

The purpose of the study is to evaluate how effective this combination treatment is when given before surgery to patients with early stage triple negative breast cancer. Participants in the study will receive either nivolumab alone first, followed by the chemotherapy drugs, or they will receive nivolumab together with the chemotherapy drugs from the start. This approach is known as neoadjuvant therapy, which means treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.

The study will follow participants through their treatment course, which includes receiving the medications through an intravenous infusion, meaning the drugs are given directly into a vein. The study will monitor the response of the cancer to the treatment, as well as the safety and tolerability of the drugs. The goal is to see if the cancer can be reduced or eliminated before surgery, improving the chances of a successful operation and potentially better long-term outcomes for patients.

]]> Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy https://clinicaltrials.eu/trial/study-on-reduced-dose-intensity-of-pembrolizumab-and-drug-combination-for-patients-with-advanced-or-metastatic-cancer-responding-to-standard-immunotherapy/ Wed, 29 Apr 2026 15:01:19 +0000 https://clinicaltrials.eu/trial/study-on-reduced-dose-intensity-of-pembrolizumab-and-drug-combination-for-patients-with-advanced-or-metastatic-cancer-responding-to-standard-immunotherapy/ This clinical trial is focused on studying various types of cancer, including lung cancer, kidney cancer, head and neck cancer, bladder cancer, triple-negative breast cancer, Merkel cell cancer, melanoma, liver cancer, colorectal cancer with a specific genetic feature called microsatellite instability, esophageal cancer, endometrial cancer, cervical cancer, stomach cancer, and certain types of skin cancer. The study involves patients whose cancer is either locally advanced or has spread to other parts of the body, and who have shown a positive response after six months of standard treatment with immunotherapy. Immunotherapy is a type of treatment that helps the immune system fight cancer.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

]]> Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA https://clinicaltrials.eu/trial/study-on-niraparib-for-patients-with-her2-negative-brca-mutated-or-triple-negative-breast-cancer-with-molecular-disease-detected-by-ctdna/ Wed, 29 Apr 2026 15:01:01 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-for-patients-with-her2-negative-brca-mutated-or-triple-negative-breast-cancer-with-molecular-disease-detected-by-ctdna/ This clinical trial is focused on studying the effects of a medication called niraparib in individuals with a specific type of breast cancer. The study involves participants who have either HER2-negative breast cancer with a mutation in the BRCA gene or triple-negative breast cancer. These types of breast cancer are identified by the presence of certain genetic markers in the blood, known as circulating tumor DNA (ctDNA), after the completion of standard treatments like surgery and chemotherapy.

The purpose of the study is to compare the safety and effectiveness of niraparib with a placebo. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will monitor the safety of niraparib by observing any side effects or changes in health status. The trial will also explore how well the medication works in preventing the return of cancer.

Participants will take the medication in the form of tablets by mouth. The study will last for a period of time, during which regular check-ups and tests will be conducted to ensure the safety and well-being of the participants. The results of this study will help determine if niraparib is a safe and effective treatment option for these specific types of breast cancer.

]]> Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ Wed, 29 Apr 2026 15:00:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-fadraciclib-for-patients-with-advanced-solid-tumors-and-lymphoma/ This clinical trial studies the effects of fadraciclib (also known as CYC065) in people with various types of advanced cancers. The study focuses on several types of solid tumors and lymphoma, including endometrial cancer, ovarian cancer, biliary tract cancer, hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, metastatic colorectal cancer, and different types of breast cancer.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

]]> Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-necvax-neo1-and-paclitaxel-albumin-bound-for-patients-with-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:00:58 +0000 https://clinicaltrials.eu/trial/study-on-necvax-neo1-and-paclitaxel-albumin-bound-for-patients-with-triple-negative-breast-cancer/ This clinical trial is focused on studying triple-negative breast cancer, a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth. The trial will explore the effects of a new treatment called NECVAX-NEO1, which is being tested as an additional therapy to the standard first-line treatment involving a type of medicine known as an anti-PD-1 monoclonal antibody. This standard treatment helps the immune system recognize and attack cancer cells. The trial will also involve the use of a medication called Abraxane, which is a form of chemotherapy used to treat breast cancer.

The purpose of the study is to assess the safety and tolerability of NECVAX-NEO1 when used alongside the existing treatment for triple-negative breast cancer. Participants in the study will receive the new treatment in addition to their regular therapy. The study will monitor participants over a period of time to observe any side effects and to see how well the treatment is tolerated. Participants will undergo regular check-ups, including blood tests and scans, to track their health and the progress of the cancer.

The study will also look at how the cancer responds to the treatment by examining tissue samples and measuring changes in the cancer’s size and spread. The trial aims to provide valuable information on whether adding NECVAX-NEO1 to the current treatment can improve outcomes for patients with triple-negative breast cancer. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1 https://clinicaltrials.eu/trial/study-of-atezolizumab-vinorelbine-and-cyclophosphamide-for-patients-with-advanced-triple-negative-breast-cancer-previously-treated-with-anti-pd-l1-pd-1/ Wed, 29 Apr 2026 15:00:56 +0000 https://clinicaltrials.eu/trial/study-of-atezolizumab-vinorelbine-and-cyclophosphamide-for-patients-with-advanced-triple-negative-breast-cancer-previously-treated-with-anti-pd-l1-pd-1/ This clinical trial is focused on studying a specific type of advanced breast cancer known as triple negative breast cancer (TNBC). This type of cancer does not have the usual receptors that many breast cancers have, which makes it more challenging to treat. The study is testing a combination of three drugs: atezolizumab, vinorelbine, and cyclophosphamide. Atezolizumab is a medication that helps the immune system fight cancer cells. Vinorelbine is a chemotherapy drug that works by stopping cancer cells from dividing and growing. Cyclophosphamide is another chemotherapy drug that helps to kill cancer cells.

The purpose of this study is to see if this combination of drugs can activate T-cells, which are a type of immune cell, in patients with TNBC who have already been treated with medications that target proteins called PD-L1 or PD-1. These proteins can help cancer cells hide from the immune system, so targeting them can help the immune system find and attack the cancer. The study will involve patients receiving these medications through infusions, which means the drugs are given directly into the bloodstream through a vein.

Participants in the study will receive the treatment over a period of time, and researchers will monitor how well the cancer responds to the treatment. They will also look at how long the response lasts, how long patients live without the cancer getting worse, and the overall safety of the treatment combination. The study aims to provide more information on how effective this treatment is for patients with this challenging type of breast cancer.

]]> Study of Adagloxad Simolenin/OBI-821, Capecitabine, and Pembrolizumab for Patients with High-Risk, Early-Stage Triple Negative Breast Cancer https://clinicaltrials.eu/trial/study-of-adagloxad-simolenin-obi-821-capecitabine-and-pembrolizumab-for-patients-with-high-risk-early-stage-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-of-adagloxad-simolenin-obi-821-capecitabine-and-pembrolizumab-for-patients-with-high-risk-early-stage-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as Triple Negative Breast Cancer (TNBC). This form of cancer is called “triple negative” because the cancer cells do not have three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and HER2/neu. The study is testing a treatment called Adagloxad Simolenin (also known by its code name OBI-822/OBI-821), which is a vaccine designed to help the immune system fight cancer cells. The purpose of the study is to see if this treatment can improve the time patients remain free from invasive cancer after their initial treatment.

Participants in the study will receive the Adagloxad Simolenin treatment, which is given as an injection under the skin. Some participants may also receive other treatments like Capecitabine, a chemotherapy drug taken by mouth, or Pembrolizumab, a type of immunotherapy given through an intravenous infusion. The study will compare the effects of these treatments to see which is more effective in preventing the return of cancer. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatments being tested.

The study will follow participants over a period of time to monitor their health and any changes in their condition. Researchers will look at how long participants remain free from cancer, their overall survival, and their quality of life during the study. The study aims to provide valuable information on the effectiveness of Adagloxad Simolenin and other treatments in managing Triple Negative Breast Cancer.

]]> Study on the Safety and Effectiveness of Durvalumab, Paclitaxel, and Drug Combinations for Patients with Metastatic Triple Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-durvalumab-paclitaxel-and-drug-combinations-for-patients-with-metastatic-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:00:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-durvalumab-paclitaxel-and-drug-combinations-for-patients-with-metastatic-triple-negative-breast-cancer/ This clinical trial is focused on studying treatments for metastatic triple-negative breast cancer (TNBC), a type of breast cancer that does not have the usual hormone receptors or the HER2 protein. The study involves several medications, including Durvalumab (also known as MEDI4736), Paclitaxel, Datopotamab deruxtecan, Oleclumab (MEDI9447), Capivasertib, and DS-8201a (Trastuzumab deruxtecan). These treatments are being tested to see how safe and effective they are when used alone or in combination.

The purpose of the study is to evaluate the safety and effectiveness of these treatments for patients with TNBC. The study is divided into two parts. In the first part, the focus is on understanding the safety and how well patients tolerate the combination of Durvalumab with other new cancer treatments, with or without Paclitaxel. The second part aims to assess how effective these combinations are in treating the cancer. Participants will receive the treatments through intravenous infusions or oral tablets, depending on the specific medication being tested.

Throughout the study, participants will be monitored for any side effects and changes in their health. The study will also track how the cancer responds to the treatments, looking for signs of improvement or progression. This research aims to find better treatment options for those with metastatic triple-negative breast cancer, offering hope for improved outcomes in the future.

]]> Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ Wed, 29 Apr 2026 15:00:29 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ This study focuses on patients with HER2-negative breast cancer who still have residual disease after receiving standard neoadjuvant chemotherapy and are at high risk of cancer returning. The main treatment being investigated is sacituzumab govitecan, which is a specialized medication that combines an antibody with an anti-cancer drug, designed to target specific cancer cells.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

]]> Study on the Safety and Effectiveness of Olaparib, Ceralasertib, and AZD1775 for Patients with Metastatic Triple Negative Breast Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-olaparib-ceralasertib-and-azd1775-for-patients-with-metastatic-triple-negative-breast-cancer/ Wed, 29 Apr 2026 15:00:22 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-olaparib-ceralasertib-and-azd1775-for-patients-with-metastatic-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as Triple Negative Breast Cancer, which is a form of cancer that does not have any of the three common receptors known to fuel most breast cancer growth. The study is investigating the effectiveness and safety of a treatment using a combination of medications. The medications being studied include Olaparib, which is already used in cancer treatment, and Ceralasertib, also known by its code name AZD6738. These medications are being tested both in combination and separately to see how well they work in treating this type of cancer.

The purpose of the study is to assess how these treatments can help patients with metastatic triple negative breast cancer, which means the cancer has spread to other parts of the body. The study will compare the effects of using Olaparib alone versus using it in combination with Ceralasertib. Participants will take these medications in the form of film-coated tablets, which are taken orally. The study will monitor the progression of the disease and any side effects that may occur during the treatment period.

Participants in the study will be randomly assigned to receive either the combination of medications or Olaparib alone. The study will take place over a period of time, with regular assessments to track the cancer’s response to the treatment. The goal is to determine which treatment option is more effective in managing the disease and improving the quality of life for patients with this challenging form of breast cancer.

]]> Study on Darolutamide and Capecitabine for Patients with Advanced Triple-Negative Androgen Receptor Positive Breast Cancer https://clinicaltrials.eu/trial/study-on-darolutamide-and-capecitabine-for-patients-with-advanced-triple-negative-androgen-receptor-positive-breast-cancer/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-darolutamide-and-capecitabine-for-patients-with-advanced-triple-negative-androgen-receptor-positive-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple-negative androgen receptor positive breast cancer. This specific form of cancer is characterized by the absence of three common receptors that are often found in breast cancer, making it more challenging to treat. The study is investigating the effectiveness of two treatments: darolutamide and capecitabine. Darolutamide, also known by its code names ODM-201 and BAY 1841788, is a medication that targets androgen receptors, which are proteins that can influence the growth of cancer cells. Capecitabine is a chemotherapy drug that is used to stop the growth of cancer cells by interfering with their DNA.

The purpose of this study is to evaluate how well these treatments work in patients with this type of breast cancer. Participants in the study will be randomly assigned to receive either darolutamide or capecitabine. The study will monitor the participants over a period of time to see how their cancer responds to the treatment. This includes checking if the cancer shrinks, remains stable, or progresses. The study will also look at the safety of the treatments by observing any side effects that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the status of their cancer. The study aims to provide valuable information on the effectiveness of these treatments, which could help improve future care for patients with triple-negative androgen receptor positive breast cancer. The study is expected to continue until the end of 2025, with results being analyzed to determine the potential benefits of darolutamide and capecitabine for this challenging form of breast cancer.

]]> Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations https://clinicaltrials.eu/trial/study-of-men1611-and-eribulin-for-advanced-metaplastic-breast-cancer-in-patients-with-pik3ca-pten-alterations/ Wed, 29 Apr 2026 14:59:17 +0000 https://clinicaltrials.eu/trial/study-of-men1611-and-eribulin-for-advanced-metaplastic-breast-cancer-in-patients-with-pik3ca-pten-alterations/ This clinical trial is focused on studying a type of breast cancer known as metaplastic breast cancer, which is advanced and cannot be surgically removed. The study is specifically looking at cases where there are changes in certain genes, called PIK3CA and PTEN. These changes can affect how the cancer grows. The trial is testing a treatment using a medication called MEN1611, which is taken as a capsule, either by itself or in combination with another medication called eribulin, which is given as an injection.

The purpose of the study is to see how effective these treatments are for patients with this specific type of breast cancer. The study is divided into two groups. In one group, patients will receive MEN1611 alone, and in the other group, patients will receive MEN1611 together with eribulin. The study will monitor how the cancer responds to these treatments over a period of time.

Participants in the study will receive the treatment and be regularly monitored by healthcare professionals. The study will track the progress of the cancer and any changes in the patient’s condition. The goal is to determine if these treatments can help control the cancer and improve the patient’s quality of life. The study will also look at any side effects that may occur during the treatment period.

]]> Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-atezolizumab-trastuzumab-and-pertuzumab-in-patients-with-early-stage-triple-negative-or-her2-breast-cancer/ Wed, 29 Apr 2026 14:59:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-atezolizumab-trastuzumab-and-pertuzumab-in-patients-with-early-stage-triple-negative-or-her2-breast-cancer/ This clinical trial is focused on studying the effects of a new treatment approach for patients with early-stage breast cancer, specifically those with triple-negative or HER2-positive types. The treatment involves using a combination of medications, including Atezolizumab (also known by its code name RO5541267), Trastuzumab, Pertuzumab, and Bevacizumab. These medications are given as solutions for infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to explore whether a short course of immunotherapy, which is a type of treatment that helps the immune system fight cancer, can increase the activity of certain immune cells in the body. The study will compare the effects of these medications on the immune system before and after treatment. Participants will receive the treatment before their standard cancer therapy, and the study will involve taking samples from the tumor to analyze changes in immune cell activity.

Throughout the study, participants will receive the medications intravenously, and their health will be monitored closely. The study aims to understand how these medications affect the immune system and whether they can improve the body’s ability to fight cancer. The trial will also look at any side effects that may occur during the treatment period and up to four weeks after surgery. This research could provide valuable insights into new ways to treat early-stage breast cancer.

]]> Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-and-pembrolizumab-for-patients-with-untreated-advanced-triple-negative-breast-cancer/ Wed, 29 Apr 2026 14:58:19 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-and-pembrolizumab-for-patients-with-untreated-advanced-triple-negative-breast-cancer/ This clinical trial is focused on studying treatments for Triple-Negative Breast Cancer that has spread to other parts of the body or cannot be removed by surgery. The study involves the use of a medication called Sacituzumab Govitecan in combination with Pembrolizumab, a type of treatment known as a monoclonal antibody. The trial will compare this combination to other treatments chosen by doctors, also combined with Pembrolizumab. The purpose of the study is to evaluate the effectiveness of these treatments in patients whose tumors express a protein called PD-L1.

Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe how the cancer responds to the treatment and to monitor any side effects. The trial aims to understand how long the treatment can prevent the cancer from getting worse and to assess the overall survival of the participants.

Throughout the study, participants will undergo regular check-ups and tests, such as imaging scans, to track the progress of their treatment. The study will also collect information on the quality of life of participants, including their physical functioning and any symptoms they experience. This information will help researchers determine the best treatment options for patients with Triple-Negative Breast Cancer in the future.

]]> Study Comparing Sacituzumab Govitecan to Physician’s Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-to-physicians-choice-treatment-for-patients-with-advanced-triple-negative-breast-cancer/ Wed, 29 Apr 2026 14:58:15 +0000 https://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-to-physicians-choice-treatment-for-patients-with-advanced-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple-negative breast cancer (TNBC). This form of cancer does not have the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and HER2. The study is specifically looking at patients with advanced stages of this cancer, either locally advanced, inoperable, or metastatic, meaning it has spread to other parts of the body. The trial involves a medication called sacituzumab govitecan, which is being compared to other treatments chosen by doctors. Sacituzumab govitecan is a type of treatment known as an antibody-drug conjugate, which combines an antibody with a drug to target cancer cells more precisely.

The purpose of the study is to compare the effectiveness of sacituzumab govitecan with other treatments in patients who have not received previous treatment for their advanced cancer or who have been treated with certain immune therapies. The study will involve administering the treatments through an intravenous infusion, which means the medication is given directly into a vein. Patients will be monitored over a period to see how their cancer responds to the treatment. The study will also look at how long patients live and how their quality of life is affected by the treatment.

Participants in the study will receive either sacituzumab govitecan or a treatment chosen by their doctor, which may include medications like paclitaxel, gemcitabine, or carboplatin. These are all chemotherapy drugs that work by stopping the growth of cancer cells. The study aims to provide more information on the best treatment options for patients with this challenging type of breast cancer. The trial is expected to continue until 2027, allowing researchers to gather comprehensive data on the effectiveness and safety of the treatments being studied.

]]> Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery https://clinicaltrials.eu/trial/study-of-capecitabine-and-pembrolizumab-for-patients-with-triple-negative-breast-cancer-after-chemoimmunotherapy-and-surgery/ Wed, 29 Apr 2026 14:57:48 +0000 https://clinicaltrials.eu/trial/study-of-capecitabine-and-pembrolizumab-for-patients-with-triple-negative-breast-cancer-after-chemoimmunotherapy-and-surgery/ This clinical trial is focused on studying Triple Negative Breast Cancer, a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth. The study is specifically for patients who have residual disease after receiving initial treatment with chemotherapy and immunotherapy before surgery. The treatment being tested in this study involves the use of two medications: capecitabine and pembrolizumab. Capecitabine is a type of chemotherapy that is taken in the form of film-coated tablets, while pembrolizumab is an immunotherapy given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate how effective the combination of capecitabine and pembrolizumab is in preventing the return of cancer after surgery. Participants in the study will receive these medications after they have undergone surgery to remove the breast tumor. The study will monitor the participants over a period of time to see how well the treatment works in keeping the cancer from coming back. The study will also look at the overall survival of participants, which means the length of time they live after starting the study, and any side effects they may experience from the treatment.

Participants will be closely followed by the study team, and their health will be monitored regularly to ensure their safety and to gather information about the treatment’s effectiveness. The study aims to provide valuable insights into whether adding capecitabine to pembrolizumab can improve outcomes for patients with Triple Negative Breast Cancer who have residual disease after initial treatment. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-farletuzumab-ecteribulin-for-patients-with-ovarian-breast-endometrial-and-lung-cancer/ Wed, 29 Apr 2026 14:57:07 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-farletuzumab-ecteribulin-for-patients-with-ovarian-breast-endometrial-and-lung-cancer/ This clinical trial is focused on studying certain types of cancer, specifically platinum-resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer (NSCLC). The treatment being tested is called farletuzumab ecteribulin, also known by its code name MORAb-202. This treatment is a special type of medication known as an antibody-drug conjugate (ADC), which is designed to target cancer cells more precisely.

The purpose of the study is to evaluate the safety and effectiveness of MORAb-202 in patients with these specific types of cancer. The study will be conducted in different phases. Initially, the focus will be on determining the safest dose of the medication. Following this, the study will further assess how well the treatment works in patients with ovarian cancer and endometrial cancer. The study will also explore different treatment schedules to find the most effective approach for patients with advanced endometrial cancer.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication will be administered directly into the bloodstream. The study will monitor participants for any side effects and measure how the cancer responds to the treatment. The goal is to gather information that could lead to the development of a new treatment option for these types of cancer.

]]>